Neoadjuvant Therapy for Hepatocellular Carcinoma

References

• Available from: https://en.jinzhao.wiki/wiki/Neoadjuvant_therapy. Accessed August 11, 2021.
   Google Scholar
• Available from: https://cancerstaging.org/. Accessed August 11, 2021.
   Google Scholar
• Pisani G, Malaspina A. Results of preoperative x-ray therapy in 343 cases of breast cancer. Tumori. 1955;41(4):406–423. doi:10.1177/030089165504100404
   PubMedGoogle Scholar
• Borgstrom S, Lindgren M. Preoperative roentgen therapy of cancer of the breast: preliminary communication. Acta radiol. 1962;58:9–16. doi:10.3109/00016926209169544
   PubMed Web of Science ®Google Scholar
• Ragaz J, Baird R, Rebbeck R, Goldie A, Coldman A, Spinelli J. Preoperative adjuvant chemotherapy (neoadjuvant) for carcinoma of the breast: rationale and safety report. Recent Results Cancer Res. 1985;98:99–105.
   PubMedGoogle Scholar
• Jacquillat C, Baillet F, Auclerc G, et al. Neoadjuvant chemotherapy of breast cancer. Drugs Exp Clin Res. 1986;12(1–3):147–152.
   PubMedGoogle Scholar
• Stearns MW, Deddish MR, Quan SH. Preoperative roentgen therapy for cancer of the rectum. Surg Gynecol Obstet. 1959;109(2):225–229.
   PubMedGoogle Scholar
• Ruff CC, Dockerty MB, Fricke RE, et al. Preoperative radiation therapy for adenocarcinoma of the rectum and rectosigmoid. Surg Gynecol Obstet. 1961;112:715–723.
   PubMedGoogle Scholar
• Smith DE, Muff NS, Shetabi H. Combined preoperative neoadjuvant radiotherapy and chemotherapy for anal and rectal cancer. Am J Surg. 1986;151(5):577–580. doi:10.1016/0002-9610(86)90552-0
   PubMed Web of Science ®Google Scholar
• Cox JD, Samson MK, Herskovic AM, et al. Cisplatin and etoposide before definitive radiation therapy for inoperable squamous carcinoma, adenocarcinoma, and large cell carcinoma of the lung: a Phase I-II study of the Radiation Therapy Oncology Group. Cancer Treat Rep. 1986;70(10):1219–1220.
   PubMedGoogle Scholar
• Kelsen DP, Hilaris B, Martini N. Neoadjuvant chemotherapy and surgery of cancer of the esophagus. Semin Surg Oncol. 1986;2(3):170–176. doi:10.1002/ssu.2980020310
   PubMedGoogle Scholar
• Gralla RJ, Kris MG. Chemotherapy in non-small cell lung cancer: results of recent trials. Semin Oncol. 1988;15(3 Suppl 4):2–5.
   PubMed Web of Science ®Google Scholar
• Schlag P, Herrmann R, Raeth U, Lehner B, Schwarz V, Herfarth C. Preoperative (neoadjuvant) chemotherapy in squamous cell cancer of the esophagus. Recent Results Cancer Res. 1988;110:14–20.
   PubMedGoogle Scholar
• Lawton FG, Redman CW, Luesley DM, et al. Neoadjuvant (cytoreductive) chemotherapy combined with intervention debulking surgery in advanced, unresected epithelial ovarian cancer. Obstet Gynecol. 1989;73(1):61–65.
   PubMed Web of Science ®Google Scholar
• Vokes EE, Bitran JD, Hoffman PC, et al. Neoadjuvant vindesine, etoposide, and cisplatin for locally advanced non-small cell lung cancer. Final report of a phase 2 study. Chest. 1989;96(1):110–113. doi:10.1378/chest.96.1.110
   PubMed Web of Science ®Google Scholar
• Chambers JT, Chambers SK, Voynick IM, et al. Neoadjuvant chemotherapy in stage X ovarian carcinoma. Gynecol Oncol. 1990;37(3):327–331. doi:10.1016/0090-8258(90)90361-N
   PubMed Web of Science ®Google Scholar
• Kelsen D. Neoadjuvant therapy for gastrointestinal cancers. Oncology. 1993;7(9):25–32; discussion 32, 35–6, 41.
   PubMedGoogle Scholar
• Sassine AM, Schulman CC. Neoadjuvant hormonal deprivation before radical prostatectomy. Eur Urol. 1993;24(Suppl 2):46–50. doi:10.1159/000474389
   PubMedGoogle Scholar
• Korde LA, Somerfield MR, Carey LA, et al. Neoadjuvant chemotherapy, endocrine therapy, and targeted therapy for breast cancer: ASCO guideline. J Clin Oncol. 2021;39(13):1485–1505. doi:10.1200/JCO.20.03399
   PubMed Web of Science ®Google Scholar
• Available from: https://www.nccn.org/guidelines/. Accessed August 11, 2021.
   Google Scholar
• Stone MJ, Klintmalm GBG, Polter D, et al. Neoadjuvant chemotherapy and liver transplantation for hepatocellular carcinoma: a pilot study in 20 patients. Gastroenterology. 1993;104(1):196–202. doi:10.1016/0016-5085(93)90852-4
   PubMed Web of Science ®Google Scholar
• Lygidakis NJ, Sgourakis G, Dedemadi G, et al. Preoperative main portal branch transection combined with liver locoregional transarterial neo and adjuvant immunochemotherapy for patients with hepatocellular carcinoma. Hepatogastroenterology. 2000;47(36):1546–1554.
   PubMedGoogle Scholar
• Fontana RJ, Hamidullah H, Nghiem H, et al. Percutaneous radiofrequency thermal ablation of hepatocellular carcinoma: a safe and effective bridge to liver transplantation. Liver Transpl. 2002;8(12):1165–1174. doi:10.1053/jlts.2002.36394
   PubMed Web of Science ®Google Scholar
• Curley SA, Izzo F, Delrio P, et al. Radiofrequency ablation of unresectable primary and metastatic hepatic malignancies: results in 123 patients. Ann Surg. 1999;230(1):1–8. doi:10.1097/00000658-199907000-00001
   PubMed Web of Science ®Google Scholar
• Akinyemiju T, Abera S, Ahmed M. The burden of primary liver cancer and underlying etiologies from 1990 to 2015 at the global, regional, and national level: results from the global burden of disease study 2015. JAMA Oncol. 2017;3(12):1683–1691. doi:10.1001/jamaoncol.2017.3055
   PubMed Web of Science ®Google Scholar
• Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–424. doi:10.3322/caac.21492
   PubMed Web of Science ®Google Scholar
• Liu K, McCaughan GW. How to select the appropriate “neoadjuvant therapy” for hepatocellular carcinoma. Expert Opin Pharmacother. 2018;19(11):1167–1170. doi:10.1080/14656566.2018.1498843
   PubMed Web of Science ®Google Scholar
• Kulik L, Heimbach JK, Zaiem F, et al. Therapies for patients with hepatocellular carcinoma awaiting liver transplantation: a systematic review and meta-analysis. Hepatology. 2018;67(1):381–400. doi:10.1002/hep.29485
   PubMed Web of Science ®Google Scholar
• Portolani N, Coniglio A, Ghidoni S, et al. Early and late recurrence after liver resection for hepatocellular carcinoma: prognostic and therapeutic implications. Ann Surg. 2006;243(2):229–235. doi:10.1097/01.sla.0000197706.21803.a1
   PubMed Web of Science ®Google Scholar
• Takeishi K, Maeda T, Tsujita E, et al. Predictors of intrahepatic multiple recurrences after curative hepatectomy for hepatocellular carcinoma. Anticancer Res. 2015;35(5):3061–3066.
   PubMed Web of Science ®Google Scholar
• Xie DY, Ren Z-G, Zhou J, et al. 2019 Chinese clinical guidelines for the management of hepatocellular carcinoma: updates and insights. Hepatobiliary Surg Nutr. 2020;9(4):452–463. doi:10.21037/hbsn-20-480
   PubMed Web of Science ®Google Scholar
• Zhu XD, Li KS, Sun HC. Adjuvant therapies after curative treatments for hepatocellular carcinoma: current status and prospects. Genes Dis. 2020;7(3):359–369. doi:10.1016/j.gendis.2020.02.002
   PubMed Web of Science ®Google Scholar
• Hirokawa F, Komeda K, Taniguchi K, et al. Is postoperative adjuvant transcatheter arterial infusion therapy effective for patients with hepatocellular carcinoma who underwent hepatectomy? A prospective randomized controlled trial. Ann Surg Oncol. 2020;27(11):4143–4152. doi:10.1245/s10434-020-08699-w
   PubMed Web of Science ®Google Scholar
• Lau WY. Future perspectives for hepatocellular carcinoma. HPB (Oxford). 2003;5(4):206–213. doi:10.1080/13651820310016779
   PubMedGoogle Scholar
• Sun Y, Wu L, Zhong Y, et al. Single-cell landscape of the ecosystem in early-relapse hepatocellular carcinoma. Cell. 2021;184(2):404–421 e16. doi:10.1016/j.cell.2020.11.041
   PubMed Web of Science ®Google Scholar
• Zheng C, Zheng L, Yoo J-K, et al. Landscape of infiltrating T cells in liver cancer revealed by single-cell sequencing. Cell. 2017;169(7):1342–1356 e16. doi:10.1016/j.cell.2017.05.035
   PubMed Web of Science ®Google Scholar
• Zhang Q, He Y, Luo N, et al. Landscape and dynamics of single immune cells in hepatocellular carcinoma. Cell. 2019;179(4):829–845 e20. doi:10.1016/j.cell.2019.10.003
   PubMed Web of Science ®Google Scholar
• Su S, Liu Q, Chen J, et al. A positive feedback loop between mesenchymal-like cancer cells and macrophages is essential to breast cancer metastasis. Cancer Cell. 2014;25(5):605–620. doi:10.1016/j.ccr.2014.03.021
   PubMed Web of Science ®Google Scholar
• Zhou SL, Yin D, Hu Z-Q, et al. A positive feedback loop between cancer stem-like cells and tumor-associated neutrophils controls hepatocellular carcinoma progression. Hepatology. 2019;70(4):1214–1230. doi:10.1002/hep.30630
   PubMed Web of Science ®Google Scholar
• Dong LQ, Peng L-H, Ma L-J, et al. Heterogeneous immunogenomic features and distinct escape mechanisms in multifocal hepatocellular carcinoma. J Hepatol. 2020;72(5):896–908. doi:10.1016/j.jhep.2019.12.014
   PubMed Web of Science ®Google Scholar
• Liu LZ, Zhang Z, Zheng B-H, et al. CCL15 recruits suppressive monocytes to facilitate immune escape and disease progression in hepatocellular carcinoma. Hepatology. 2019;69(1):143–159. doi:10.1002/hep.30134
   PubMed Web of Science ®Google Scholar
• Ringelhan M, Pfister D, O’Connor T, et al. The immunology of hepatocellular carcinoma. Nat Immunol. 2018;19(3):222–232. doi:10.1038/s41590-018-0044-z
   PubMed Web of Science ®Google Scholar
• Zheng H, Pomyen Y, Hernandez MO, et al. Single-cell analysis reveals cancer stem cell heterogeneity in hepatocellular carcinoma. Hepatology. 2018;68(1):127–140. doi:10.1002/hep.29778
   PubMed Web of Science ®Google Scholar
• Dong LQ, Shi Y, Ma L-J, et al. Spatial and temporal clonal evolution of intrahepatic cholangiocarcinoma. J Hepatol. 2018;69(1):89–98. doi:10.1016/j.jhep.2018.02.029
   PubMed Web of Science ®Google Scholar
• Losic B, Craig AJ, Villacorta-Martin C, et al. Intratumoral heterogeneity and clonal evolution in liver cancer. Nat Commun. 2020;11(1):291. doi:10.1038/s41467-019-14050-z
   PubMed Web of Science ®Google Scholar
• Craig AJ, von Felden J, Garcia-Lezana T, et al. Tumour evolution in hepatocellular carcinoma. Nat Rev Gastroenterol Hepatol. 2020;17(3):139–152. doi:10.1038/s41575-019-0229-4
   PubMed Web of Science ®Google Scholar
• Ding X, He M, Chan AWH, et al. Genomic and epigenomic features of primary and recurrent hepatocellular carcinomas. Gastroenterology. 2019;157(6):1630–1645 e6. doi:10.1053/j.gastro.2019.09.005
   PubMed Web of Science ®Google Scholar
• Wang W, Mauleon R, Hu Z, et al. Genomic variation in 3010 diverse accessions of Asian cultivated rice. Nature. 2018;557(7703):43–49. doi:10.1038/s41586-018-0063-9
   PubMed Web of Science ®Google Scholar
• Haas NB, Manola J, Uzzo RG, et al. Adjuvant sunitinib or sorafenib for high-risk, non-metastatic renal-cell carcinoma (ECOG-ACRIN E2805): a double-blind, placebo-controlled, randomised, Phase 3 trial. Lancet. 2016;387(10032):2008–2016. doi:10.1016/S0140-6736(16)00559-6
   PubMed Web of Science ®Google Scholar
• Ikeda K, Kudo M, Kawazoe S, et al. Phase 2 study of lenvatinib in patients with advanced hepatocellular carcinoma. J Gastroenterol. 2017;52(4):512–519. doi:10.1007/s00535-016-1263-4
   PubMed Web of Science ®Google Scholar
• Zhai H, Zhong W, Yang X, et al. Neoadjuvant and adjuvant epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) therapy for lung cancer. Transl Lung Cancer Res. 2015;4(1):82–93. doi:10.3978/j.issn.2218-6751.2014.11.08
   PubMedGoogle Scholar
• Koulouris A, Tsagkaris C, Spyrou V, et al. Hepatocellular carcinoma: an overview of the changing landscape of treatment options. J Hepatocell Carcinoma. 2021;8:387–401. doi:10.2147/JHC.S300182
   PubMed Web of Science ®Google Scholar
• Jiang Y, Sun A, Zhao Y, et al. Proteomics identifies new therapeutic targets of early-stage hepatocellular carcinoma. Nature. 2019;567(7747):257–261. doi:10.1038/s41586-019-0987-8
   PubMed Web of Science ®Google Scholar
• Gao Q, Zhu H, Dong L, et al. Integrated proteogenomic characterization of HBV-related hepatocellular carcinoma. Cell. 2019;179(2):561–577 e22. doi:10.1016/j.cell.2019.08.052
   PubMed Web of Science ®Google Scholar
• Xue R, Chen L, Zhang C, et al. Genomic and transcriptomic profiling of combined hepatocellular and intrahepatic cholangiocarcinoma reveals distinct molecular subtypes. Cancer Cell. 2019;35(6):932–947 e8. doi:10.1016/j.ccell.2019.04.007
   PubMed Web of Science ®Google Scholar
• Duan M, Hao J, Cui S, et al. Diverse modes of clonal evolution in HBV-related hepatocellular carcinoma revealed by single-cell genome sequencing. Cell Res. 2018;28(3):359–373. doi:10.1038/cr.2018.11
   PubMed Web of Science ®Google Scholar
• Zhang Q, Lou Y, Yang J, et al. Integrated multiomic analysis reveals comprehensive tumour heterogeneity and novel immunophenotypic classification in hepatocellular carcinomas. Gut. 2019;68(11):2019–2031. doi:10.1136/gutjnl-2019-318912
   PubMed Web of Science ®Google Scholar
• Peng C, Li C, Liu C, et al. The outcome of the HCC patients underwent ALPPS: retrospective study. Medicine. 2019;98(38):e17182. doi:10.1097/MD.0000000000017182
   PubMed Web of Science ®Google Scholar
• Vennarecci G, Grazi GL, Sperduti I, et al. ALPPS for primary and secondary liver tumors. Int J Surg. 2016;30:38–44. doi:10.1016/j.ijsu.2016.04.031
   PubMed Web of Science ®Google Scholar
• Zhang J, Huang H, Bian J, et al. Safety, feasibility, and efficacy of associating liver partition and portal vein ligation for staged hepatectomy in treating hepatocellular carcinoma: a systematic review. Ann Transl Med. 2020;8(19):1246. doi:10.21037/atm-20-2214
   PubMed Web of Science ®Google Scholar
• Fitzmorris P, Shoreibah M, Anand BS, et al. Management of hepatocellular carcinoma. J Cancer Res Clin Oncol. 2015;141(5):861–876. doi:10.1007/s00432-014-1806-0
   PubMed Web of Science ®Google Scholar
• Llovet JM, Zucman-Rossi J, Pikarsky E, et al. Hepatocellular carcinoma. Nat Rev Dis Primers. 2016;2:16018. doi:10.1038/nrdp.2016.18
   PubMed Web of Science ®Google Scholar
• Fisher B. Biological and clinical considerations regarding the use of surgery and chemotherapy in the treatment of primary breast cancer. Cancer. 1977;40(1 Suppl):574–587.
   PubMed Web of Science ®Google Scholar
• Meirelles Junior RF, Salvalaggio P, Rezende MBD, et al. Liver transplantation: history, outcomes and perspectives. Einstein. 2015;13(1):149–152. doi:10.1590/S1679-45082015RW3164
   PubMedGoogle Scholar
• Stone MJ, Klintmalm G, Polter D, Husberg B, Egorin MJ. Neoadjuvant chemotherapy and orthotopic liver transplantation for hepatocellular carcinoma. Transplantation. 1989;48(2):344–347.
   PubMed Web of Science ®Google Scholar
• Rizzi PM, Ryder SD, Ramage JK, et al. Neoadjuvant chemotherapy after liver transplantation for hepatocellular carcinoma. Transplant Proc. 1994;26(6):3568–3569.
   PubMed Web of Science ®Google Scholar
• Holman M, Harrison D, Stewart A, et al. Neoadjuvant chemotherapy and orthotopic liver transplantation for hepatocellular carcinoma. N J Med. 1995;92(8):519–522.
   PubMedGoogle Scholar
• Arcement CM, Towbin RB, Meza MP, et al. Intrahepatic chemoembolization in unresectable pediatric liver malignancies. Pediatr Radiol. 2000;30(11):779–785. doi:10.1007/s002470000296
   PubMed Web of Science ®Google Scholar
• Paye F, Jagot P, Vilgrain V, et al. Preoperative chemoembolization of hepatocellular carcinoma: a comparative study. Arch Surg. 1998;133(7):767–772. doi:10.1001/archsurg.133.7.767
   PubMedGoogle Scholar
• Paye F, Farges O, Dahmane M, et al. Cytolysis following chemoembolization for hepatocellular carcinoma. Br J Surg. 1999;86(2):176–180. doi:10.1046/j.1365-2168.1999.01014.x
   PubMed Web of Science ®Google Scholar
• Yoshida T, Sakon M, Umeshita K, et al. Appraisal of transarterial immunoembolization for hepatocellular carcinoma: a clinicopathologic study. J Clin Gastroenterol. 2001;32(1):59–65. doi:10.1097/00004836-200101000-00014
   PubMed Web of Science ®Google Scholar
• Ramsey DE, Kernagis LY, Soulen MC, et al. Chemoembolization of hepatocellular carcinoma. J Vasc Interv Radiol. 2002;13(9 Pt 2):S211–21. doi:10.1016/S1051-0443(07)61789-8
   PubMed Web of Science ®Google Scholar
• Zhang T, Zhang L, Xu Y, et al.Neoadjuvant therapy and immunotherapy strategies for hepatocellular carcinoma. Am J Cancer Res. 2020;10:1658.
   PubMed Web of Science ®Google Scholar
• Galastri FL, Nasser F, Affonso BB, et al. Imaging response predictors following drug eluting beads chemoembolization in the neoadjuvant liver transplant treatment of hepatocellular carcinoma. World J Hepatol. 2020;12(1):21–33. doi:10.4254/wjh.v12.i1.21
   PubMed Web of Science ®Google Scholar
• Raoul JL, Forner A, Bolondi L, et al. Updated use of TACE for hepatocellular carcinoma treatment: how and when to use it based on clinical evidence. Cancer Treat Rev. 2019;72:28–36. doi:10.1016/j.ctrv.2018.11.002
   PubMed Web of Science ®Google Scholar
• Affonso BB, Galastri FL, Filho JM, et al. Long-term outcomes of hepatocellular carcinoma that underwent chemoembolization for bridging or downstaging. World J Gastroenterol. 2019;25(37):5687–5701. doi:10.3748/wjg.v25.i37.5687
   PubMed Web of Science ®Google Scholar
• Lee BH, Lee D-S, Cho CW, et al. Role and limitation of neoadjuvant hepatic arterial infusion chemotherapy in advanced hepatocelluar carcinoma patients with Child-Pugh class A. World J Surg Oncol. 2019;17(1):143. doi:10.1186/s12957-019-1685-6
   PubMed Web of Science ®Google Scholar
• Li C, Wang M-D, Lu L, et al. Preoperative transcatheter arterial chemoembolization for surgical resection of huge hepatocellular carcinoma (>/= 10 cm): a multicenter propensity matching analysis. Hepatol Int. 2019;13(6):736–747. doi:10.1007/s12072-019-09981-0
   PubMed Web of Science ®Google Scholar
• Chang Y, Jeong SW, Young Jang J, et al. Recent updates of transarterial chemoembolilzation in hepatocellular carcinoma. Int J Mol Sci. 2020;21(21). doi:10.3390/ijms21218165
   Web of Science ®Google Scholar
• Hamaoka M, Kobayashi T, Kuroda S, et al. Hepatectomy after down-staging of hepatocellular carcinoma with portal vein tumor thrombus using chemoradiotherapy: a retrospective cohort study. Int J Surg. 2017;44:223–228. doi:10.1016/j.ijsu.2017.06.082
   PubMed Web of Science ®Google Scholar
• Chong JU, Choi GH, Han DH, et al. Downstaging with localized concurrent chemoradiotherapy can identify optimal surgical candidates in hepatocellular carcinoma with portal vein tumor thrombus. Ann Surg Oncol. 2018;25(11):3308–3315. doi:10.1245/s10434-018-6653-9
   PubMed Web of Science ®Google Scholar
• Zhang Z, Liu Q, He J, et al. The effect of preoperative transcatheter hepatic arterial chemoembolization on disease-free survival after hepatectomy for hepatocellular carcinoma. Cancer. 2000;89(12):2606–2612. doi:10.1002/1097-0142(20001215)89:12<2606::AID-CNCR13>3.0.CO;2-T
   PubMed Web of Science ®Google Scholar
• Shi HY, Wang S-N, Wang SC, et al. Preoperative transarterial chemoembolization and resection for hepatocellular carcinoma: a nationwide Taiwan database analysis of long-term outcome predictors. J Surg Oncol. 2014;109(5):487–493. doi:10.1002/jso.23521
   PubMed Web of Science ®Google Scholar
• Lee KT, Lu Y-W, Wang S-N, et al. The effect of preoperative transarterial chemoembolization of resectable hepatocellular carcinoma on clinical and economic outcomes. J Surg Oncol. 2009;99(6):343–350. doi:10.1002/jso.21248
   PubMed Web of Science ®Google Scholar
• Yeh ML, Huang C-I, Huang C-F, et al. Neoadjuvant transcatheter arterial chemoembolization does not provide survival benefit compared to curative therapy alone in single hepatocellular carcinoma. Kaohsiung J Med Sci. 2015;31(2):77–82. doi:10.1016/j.kjms.2014.11.003
   PubMed Web of Science ®Google Scholar
• Chua TC, Liauw W, Saxena A, et al. Systematic review of neoadjuvant transarterial chemoembolization for resectable hepatocellular carcinoma. Liver Int. 2010;30(2):166–174. doi:10.1111/j.1478-3231.2009.02166.x
   PubMed Web of Science ®Google Scholar
• Zhou WP, Lai ECH, Li A-J, et al. A prospective, randomized, controlled trial of preoperative transarterial chemoembolization for resectable large hepatocellular carcinoma. Ann Surg. 2009;249(2):195–202. doi:10.1097/SLA.0b013e3181961c16
   PubMed Web of Science ®Google Scholar
• Han G, Berhane S, Toyoda H, et al. Prediction of survival among patients receiving transarterial chemoembolization for hepatocellular carcinoma: a response-based approach. Hepatology. 2020;72(1):198–212. doi:10.1002/hep.31022
   PubMed Web of Science ®Google Scholar
• Korita PV, Wakai T, Shirai Y, et al. Multidrug resistance-associated protein 2 determines the efficacy of cisplatin in patients with hepatocellular carcinoma. Oncol Rep. 2010;23(4):965–972. doi:10.3892/or_00000721
   PubMed Web of Science ®Google Scholar
• Lin H, Li X, Liu Y, et al. Neoadjuvant radiotherapy provided survival benefit compared to adjuvant radiotherapy for hepatocellular carcinoma. ANZ J Surg. 2018;88(10):E718–E724. doi:10.1111/ans.14387
   PubMed Web of Science ®Google Scholar
• Wei X, Jiang Y, Zhang X, et al. Neoadjuvant three-dimensional conformal radiotherapy for resectable hepatocellular carcinoma with portal vein tumor thrombus: a randomized, open-label, multicenter controlled study. J Clin Oncol. 2019;37(24):2141–2151. doi:10.1200/JCO.18.02184
   PubMed Web of Science ®Google Scholar
• Wada H, Sasaki Y, Yamada T, et al. Successful preoperative treatment for hepatocellular carcinoma with tumor thrombus in the major portal branch by three-dimensional conformal radiation therapy–two case reports. Hepatogastroenterology. 2005;52(62):343–347.
   PubMedGoogle Scholar
• Kamiyama T, Nakanishi K, Yokoo H, et al. Efficacy of preoperative radiotherapy to portal vein tumor thrombus in the main trunk or first branch in patients with hepatocellular carcinoma. Int J Clin Oncol. 2007;12(5):363–368. doi:10.1007/s10147-007-0701-y
   PubMed Web of Science ®Google Scholar
• Katz AW, Chawla S, Qu Z, et al. Stereotactic hypofractionated radiation therapy as a bridge to transplantation for hepatocellular carcinoma: clinical outcome and pathologic correlation. Int J Radiat Oncol Biol Phys. 2012;83(3):895–900. doi:10.1016/j.ijrobp.2011.08.032
   PubMed Web of Science ®Google Scholar
• Hasan S, Thai N, Uemura T, et al. Hepatocellular carcinoma with child Pugh-A Cirrhosis treated with stereotactic body radiotherapy. World J Gastrointest Surg. 2017;9(12):256–263. doi:10.4240/wjgs.v9.i12.256
   PubMed Web of Science ®Google Scholar
• Kulik LM, Carr BI, Mulcahy MF, et al. Safety and efficacy of 90Y radiotherapy for hepatocellular carcinoma with and without portal vein thrombosis. Hepatology. 2008;47(1):71–81. doi:10.1002/hep.21980
   PubMed Web of Science ®Google Scholar
• Salem R, Gordon AC, Mouli S, et al. Y90 radioembolization significantly prolongs time to progression compared with chemoembolization in patients with hepatocellular carcinoma. Gastroenterology. 2016;151(6):1155–1163 e2. doi:10.1053/j.gastro.2016.08.029
   PubMed Web of Science ®Google Scholar
• Tabone M, Calvo A, Russolillo N, et al. Downstaging unresectable hepatocellular carcinoma by radioembolization using 90-yttrium resin microspheres: a single center experience. J Gastrointest Oncol. 2020;11(1):84–90. doi:10.21037/jgo.2019.06.01
   PubMed Web of Science ®Google Scholar
• Labgaa I, Tabrizian P, Titano J, et al. Feasibility and safety of liver transplantation or resection after transarterial radioembolization with Yttrium-90 for unresectable hepatocellular carcinoma. HPB (Oxford). 2019;21(11):1497–1504. doi:10.1016/j.hpb.2019.03.360
   PubMed Web of Science ®Google Scholar
• Edeline J, Lenoir L, Boudjema K, et al. Volumetric changes after (90)y radioembolization for hepatocellular carcinoma in cirrhosis: an option to portal vein embolization in a preoperative setting? Ann Surg Oncol. 2013;20(8):2518–2525. doi:10.1245/s10434-013-2906-9
   PubMed Web of Science ®Google Scholar
• Lau WY, Sangro B, Chen P-J, et al. Treatment for hepatocellular carcinoma with portal vein tumor thrombosis: the emerging role for radioembolization using yttrium-90. Oncology. 2013;84(5):311–318. doi:10.1159/000348325
   PubMed Web of Science ®Google Scholar
• Lewandowski RJ, Donahue L, Chokechanachaisakul A, et al. 90 Y radiation lobectomy: outcomes following surgical resection in patients with hepatic tumors and small future liver remnant volumes. J Surg Oncol. 2016;114(1):99–105. doi:10.1002/jso.24269
   PubMed Web of Science ®Google Scholar
• Spreafico C, Sposito C, Vaiani M, et al. Development of a prognostic score to predict response to Yttrium-90 radioembolization for hepatocellular carcinoma with portal vein invasion. J Hepatol. 2018;68(4):724–732. doi:10.1016/j.jhep.2017.12.026
   PubMed Web of Science ®Google Scholar
• She WH, Cheung TT, Yau TCC, et al. Survival analysis of transarterial radioembolization with yttrium-90 for hepatocellular carcinoma patients with HBV infection. Hepatobiliary Surg Nutr. 2014;3(4):185–193. doi:10.3978/j.issn.2304-3881.2014.07.09
   PubMedGoogle Scholar
• Vilgrain V, Pereira H, Assenat E, et al. Efficacy and safety of selective internal radiotherapy with yttrium-90 resin microspheres compared with sorafenib in locally advanced and inoperable hepatocellular carcinoma (SARAH): an open-label randomised controlled phase 3 trial. Lancet Oncol. 2017;18(12):1624–1636. doi:10.1016/S1470-2045(17)30683-6
   PubMed Web of Science ®Google Scholar
• Chow PKH, Gandhi M, Tan S-B, et al. SIRveNIB: selective internal radiation therapy versus sorafenib in asia-pacific patients with hepatocellular carcinoma. J Clin Oncol. 2018;36(19):1913–1921. doi:10.1200/JCO.2017.76.0892
   PubMed Web of Science ®Google Scholar
• Cheng S, Chen M, Cai J, et al. Chinese expert consensus on multidisciplinary diagnosis and treatment of hepatocellular carcinoma with portal vein tumor thrombus (2018 Edition). Liver Cancer. 2020;9(1):28–40. doi:10.1159/000503685
   PubMed Web of Science ®Google Scholar
• Shiina S, Tagawa K, Unuma T, et al. Percutaneous ethanol injection therapy for hepatocellular carcinoma. A histopathologic study. Cancer. 1991;68(7):1524–1530. doi:10.1002/1097-0142(19911001)68:7<1524::AID-CNCR2820680711>3.0.CO;2-O
   PubMed Web of Science ®Google Scholar
• Shiina S, Yasuda H, Muto H, et al. Percutaneous ethanol injection in the treatment of liver neoplasms. AJR Am J Roentgenol. 1987;149(5):949–952. doi:10.2214/ajr.149.5.949
   PubMed Web of Science ®Google Scholar
• Livraghi T, Festi D, Monti F, et al. US-guided percutaneous alcohol injection of small hepatic and abdominal tumors. Radiology. 1986;161(2):309–312. doi:10.1148/radiology.161.2.3020612
   PubMed Web of Science ®Google Scholar
• Lee SJ, Cho E-H, Kim R, et al. Hepatectomy, combined with intraoperative radiofrequency ablation in patients with multiple hepatocellular carcinomas. Korean J Hepatobiliary Pancreat Surg. 2015;19(3):98–102. doi:10.14701/kjhbps.2015.19.3.98
   PubMedGoogle Scholar
• Amersi FF, McElrath-Garza A, Ahmad A, et al. Long-term survival after radiofrequency ablation of complex unresectable liver tumors. Arch Surg. 2006;141(6):581–7; discussion 587–8. doi:10.1001/archsurg.141.6.581
   PubMedGoogle Scholar
• Pawlik TM, Izzo F, Cohen DS, et al. Combined resection and radiofrequency ablation for advanced hepatic malignancies: results in 172 patients. Ann Surg Oncol. 2003;10(9):1059–1069. doi:10.1245/ASO.2003.03.026
   PubMed Web of Science ®Google Scholar
• Xu LL, Zhang M, Yi P-S, et al. Hepatic resection combined with radiofrequency ablation versus hepatic resection alone for multifocal hepatocellular carcinomas: a meta-analysis. J Huazhong Univ Sci Technolog Med Sci. 2017;37(6):974–980. doi:10.1007/s11596-017-1836-3
   PubMedGoogle Scholar
• Lu DS, Yu NC, Raman SS, et al. Percutaneous radiofrequency ablation of hepatocellular carcinoma as a bridge to liver transplantation. Hepatology. 2005;41(5):1130–1137. doi:10.1002/hep.20688
   PubMed Web of Science ®Google Scholar
• Barakat O, Wood RP, Ozaki CF, et al. Morphological features of advanced hepatocellular carcinoma as a predictor of downstaging and liver transplantation: an intention-to-treat analysis. Liver Transpl. 2010;16(3):289–299. doi:10.1002/lt.21994
   PubMed Web of Science ®Google Scholar
• Mazzaferro V, Battiston C, Perrone S, et al. Radiofrequency ablation of small hepatocellular carcinoma in cirrhotic patients awaiting liver transplantation: a prospective study. Ann Surg. 2004;240(5):900–909. doi:10.1097/01.sla.0000143301.56154.95
   PubMed Web of Science ®Google Scholar
• Yao FY, Kerlan RK, Hirose R, et al. Excellent outcome following down-staging of hepatocellular carcinoma prior to liver transplantation: an intention-to-treat analysis. Hepatology. 2008;48(3):819–827. doi:10.1002/hep.22412
   PubMed Web of Science ®Google Scholar
• Ersan V, Barut B, Yilmaz S. The timing of liver transplantation following downstaging: wait of not to wait? J Gastrointest Cancer. 2020;51(4):1152–1156. doi:10.1007/s12029-020-00491-z
   PubMed Web of Science ®Google Scholar
• Lu MD, Xu H-X, Xie X-Y, et al. Percutaneous microwave and radiofrequency ablation for hepatocellular carcinoma: a retrospective comparative study. J Gastroenterol. 2005;40(11):1054–1060. doi:10.1007/s00535-005-1671-3
   PubMed Web of Science ®Google Scholar
• Li Q, Chen K, Huang W, et al. Minimally invasive photothermal ablation assisted by laparoscopy as an effective preoperative neoadjuvant treatment for orthotopic hepatocellular carcinoma. Cancer Lett. 2021;496:169–178. doi:10.1016/j.canlet.2020.09.024
   PubMed Web of Science ®Google Scholar
• Thornton LM, Cabrera R, Kapp M, et al. Radiofrequency vs microwave ablation after neoadjuvant transarterial bland and drug-eluting microsphere chembolization for the treatment of hepatocellular carcinoma. Curr Probl Diagn Radiol. 2017;46(6):402–409. doi:10.1067/j.cpradiol.2017.02.006
   PubMed Web of Science ®Google Scholar
• Seki T, Wakabayashi M, Nakagawa T, et al. Percutaneous microwave coagulation therapy for patients with small hepatocellular carcinoma: comparison with percutaneous ethanol injection therapy. Cancer. 1999;85(8):1694–1702. doi:10.1002/(SICI)1097-0142(19990415)85:8<1694::AID-CNCR8>3.0.CO;2-3
   PubMed Web of Science ®Google Scholar
• Rizzo A. Tyrosine kinase inhibitors plus immune checkpoint inhibitors as neoadjuvant therapy for hepatocellular carcinoma: an emerging option? Expert Opin Investig Drugs. 2021;2021:1–3.
   Google Scholar
• Pinato DJ, Fessas P, Sapisochin G, Marron TU. Perspectives on the neoadjuvant use of immunotherapy in hepatocellular carcinoma. Hepatology. 2020;74:483–490.
   Web of Science ®Google Scholar
• Dikilitas M. Why adjuvant and neoadjuvant therapy failed in HCC. Can the new immunotherapy be expected to be better? J Gastrointest Cancer. 2020;51(4):1193–1196. doi:10.1007/s12029-020-00497-7
   PubMed Web of Science ®Google Scholar
• Llovet JM, Ricci S, Mazzaferro V, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 2008;359(4):378–390. doi:10.1056/NEJMoa0708857
   PubMed Web of Science ®Google Scholar
• Bruix J, Qin S, Merle P, et al. Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2017;389(10064):56–66. doi:10.1016/S0140-6736(16)32453-9
   PubMed Web of Science ®Google Scholar
• Kudo M, Finn RS, Qin S, et al. Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial. Lancet. 2018;391(10126):1163–1173. doi:10.1016/S0140-6736(18)30207-1
   PubMed Web of Science ®Google Scholar
• Abou-Alfa GK, Meyer T, Cheng A-L, et al. Cabozantinib in patients with advanced and progressing hepatocellular carcinoma. N Engl J Med. 2018;379(1):54–63. doi:10.1056/NEJMoa1717002
   PubMed Web of Science ®Google Scholar
• Vitale A, Volk ML, Pastorelli D, et al. Use of sorafenib in patients with hepatocellular carcinoma before liver transplantation: a cost-benefit analysis while awaiting data on sorafenib safety. Hepatology. 2010;51(1):165–173. doi:10.1002/hep.23260
   PubMed Web of Science ®Google Scholar
• Truesdale AE, Caldwell SH, Shah NL, et al. Sorafenib therapy for hepatocellular carcinoma prior to liver transplant is associated with increased complications after transplant. Transpl Int. 2011;24(10):991–998. doi:10.1111/j.1432-2277.2011.01299.x
   PubMed Web of Science ®Google Scholar
• Hoffmann K, Ganten T, Gotthardtp D, et al. Impact of neo-adjuvant Sorafenib treatment on liver transplantation in HCC patients - a prospective, randomized, double-blind, Phase III trial. BMC Cancer. 2015;15:392. doi:10.1186/s12885-015-1373-z
   PubMed Web of Science ®Google Scholar
• Golse N, Radenne S, Rode A, et al. Liver transplantation after neoadjuvant sorafenib therapy: preliminary experience and literature review. Exp Clin Transplant. 2018;16(2):227–236. doi:10.6002/ect.2015.0299
   PubMed Web of Science ®Google Scholar
• Eilard MS, Andersson M, Naredi P, et al. A prospective clinical trial on sorafenib treatment of hepatocellular carcinoma before liver transplantation. BMC Cancer. 2019;19(1):568. doi:10.1186/s12885-019-5760-8
   PubMed Web of Science ®Google Scholar
• Ye SL, Chen X, Yang J, et al. Evaluation of sorafenib in Chinese unresectable hepatocellular carcinoma patients with prior surgery and portal vein tumor thrombosis: a subset analysis of GIDEON study data. Tumour Biol. 2017;39(3):1010428317695030. doi:10.1177/1010428317695030
   Google Scholar
• Barbier L, Fuks D, Pessaux P, et al. Safety of liver resection for hepatocellular carcinoma after sorafenib therapy: a multicenter case-matched study. Ann Surg Oncol. 2013;20(11):3603–3609. doi:10.1245/s10434-013-3029-z
   PubMed Web of Science ®Google Scholar
• Bouattour M, Rosmorduc FL, Scatton O. BIOSHARE multicenter neoadjuvant phase 2 study: results of preoperative sorafenib in patients with resectable hepatocellular carcinoma (HCC)-From GERCOR IRC. J Clin Oncol. 2016;34:252–252. doi:10.1200/jco.2016.34.4_suppl.252
   Web of Science ®Google Scholar
• Mazzaferro V, Citterio D, Bhoori S, et al. Liver transplantation in hepatocellular carcinoma after tumour downstaging (XXL): a randomised, controlled, phase 2b/3 trial. Lancet Oncol. 2020;21(7):947–956. doi:10.1016/S1470-2045(20)30224-2
   PubMed Web of Science ®Google Scholar
• Demir T, Lee SS, Kaseb AO. Systemic therapy of liver cancer. Adv Cancer Res. 2021;149:257–294.
   PubMed Web of Science ®Google Scholar
• El-Khoueiry AB, Hanna DL, Llovet J, et al. Cabozantinib: an evolving therapy for hepatocellular carcinoma. Cancer Treat Rev. 2021;98:102221. doi:10.1016/j.ctrv.2021.102221
   PubMed Web of Science ®Google Scholar
• Bregni G, Vandeputte C, Pretta A, et al. Rationale and design of REGINA, a phase II trial of neoadjuvant regorafenib, nivolumab, and short-course radiotherapy in stage II and III rectal cancer. Acta Oncol. 2021;60(4):549–553. doi:10.1080/0284186X.2020.1871067
   PubMed Web of Science ®Google Scholar
• Dang RP, McFarland D, Le VH, et al. Neoadjuvant therapy in differentiated thyroid cancer. Int J Surg Oncol. 2016;2016:3743420. doi:10.1155/2016/3743420
   PubMedGoogle Scholar
• Kim M, Ahn J, Song DE, et al. Real-world experience of lenvatinib in patients with advanced anaplastic thyroid cancer. Endocrine. 2021;71(2):427–433. doi:10.1007/s12020-020-02425-y
   PubMed Web of Science ®Google Scholar
• Berhane S, Fox R, García-Fiñana M, et al. Using prognostic and predictive clinical features to make personalised survival prediction in advanced hepatocellular carcinoma patients undergoing sorafenib treatment. Br J Cancer. 2019;121(2):117–124. doi:10.1038/s41416-019-0488-4
   PubMed Web of Science ®Google Scholar
• Nault JC, Villanueva A. Intratumor molecular and phenotypic diversity in hepatocellular carcinoma. Clin Cancer Res. 2015;21(8):1786–1788. doi:10.1158/1078-0432.CCR-14-2602
   PubMed Web of Science ®Google Scholar
• Jin H, Shi Y, Lv Y, et al. EGFR activation limits the response of liver cancer to lenvatinib. Nature. 2021;595(7869):730–734. doi:10.1038/s41586-021-03741-7
   PubMed Web of Science ®Google Scholar
• Subbiah V, Lassen U, Élez E, et al. Dabrafenib plus trametinib in patients with BRAF(V600E)-mutated biliary tract cancer (ROAR): a phase 2, open-label, single-arm, multicentre basket trial. Lancet Oncol. 2020;21(9):1234–1243. doi:10.1016/S1470-2045(20)30321-1
   PubMed Web of Science ®Google Scholar
• Rimassa L, Danesi R, Pressiani T, et al. Management of adverse events associated with tyrosine kinase inhibitors: improving outcomes for patients with hepatocellular carcinoma. Cancer Treat Rev. 2019;77:20–28. doi:10.1016/j.ctrv.2019.05.004
   PubMed Web of Science ®Google Scholar
• Matsui M, Machida S, Itani-Yohda T, et al. Downregulation of the proteasome subunits, transporter, and antigen presentation in hepatocellular carcinoma, and their restoration by interferon-gamma. J Gastroenterol Hepatol. 2002;17(8):897–907. doi:10.1046/j.1440-1746.2002.02837.x
   PubMed Web of Science ®Google Scholar
• Kurebayashi Y, Ojima H, Tsujikawa H, et al. Landscape of immune microenvironment in hepatocellular carcinoma and its additional impact on histological and molecular classification. Hepatology. 2018;68(3):1025–1041. doi:10.1002/hep.29904
   PubMed Web of Science ®Google Scholar
• Zhu AX, Ikeda FR, Sung MW, et al. A phase Ib study of lenvatinib (LEN) plus pembrolizumab (PEMBRO) in unresectable hepatocellular carcinoma (uHCC). J Clin Oncol. 2020;20(38):v286–v287.
   Google Scholar
• Finn RS, Ikeda M, Zhu AX, et al. Phase Ib study of lenvatinib plus pembrolizumab in patients with unresectable hepatocellular carcinoma. J Clin Oncol. 2020;38(26):2960–2970. doi:10.1200/JCO.20.00808
   PubMed Web of Science ®Google Scholar
• Rusch VW, Johnson CJ, Wistuba II, et al. Neoadjuvant atezolizumab in resectable non-small cell lung cancer (NSCLC): initial results from a multicenter study (LCMC3). J Clin Oncol. 2018;20(36):8541.
   Web of Science ®Google Scholar
• Kaseb AO, Tran Cao DD, Abugabal YI, et al. Randomized, open-label, perioperative phase II study evaluating nivolumab alone or nivolumab plus ipilimumab in patients with resectable HCC. J Clin Oncol. 2020;1(38):185.
   Google Scholar
• Schwacha-Eipper B, Minciuna I, Banz V, et al. Immunotherapy as a downstaging therapy for liver transplantation. Hepatology. 2020;72(4):1488–1490. doi:10.1002/hep.31234
   PubMed Web of Science ®Google Scholar
• Casak SJ, Donoghue M, Fashoyin-Aje L, et al. FDA approval summary: atezolizumab plus bevacizumab for the treatment of patients with advanced unresectable or metastatic hepatocellular carcinoma. Clin Cancer Res. 2021;27(7):1836–1841. doi:10.1158/1078-0432.CCR-20-3407
   PubMed Web of Science ®Google Scholar
• Finn RS, Qin S, Ikeda M, et al. Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma. N Engl J Med. 2020;382(20):1894–1905. doi:10.1056/NEJMoa1915745
   PubMed Web of Science ®Google Scholar
• Hack SP, Spahn J, Chen M, et al. IMbrave 050: a Phase III trial of atezolizumab pParklus bevacizumab in high-risk hepatocellular carcinoma after curative resection or ablation. Future Oncol. 2020;16(15):975–989. doi:10.2217/fon-2020-0162
   PubMed Web of Science ®Google Scholar
• Lee MS, Ryoo B-Y, Hsu C-H, et al. Atezolizumab with or without bevacizumab in unresectable hepatocellular carcinoma (GO30140): an open-label, multicentre, phase 1b study. Lancet Oncol. 2020;21(6):808–820. doi:10.1016/S1470-2045(20)30156-X
   PubMed Web of Science ®Google Scholar
• Pinato DJ, Fessas P, Sapisochin G, et al. Perspectives on the neoadjuvant use of immunotherapy in hepatocellular carcinoma. Hepatology. 2021;74(1):483–490. doi:10.1002/hep.31697
   PubMed Web of Science ®Google Scholar
• Iwamoto H, Shimose S, Noda Y, et al. Initial experience of atezolizumab plus bevacizumab for unresectable hepatocellular carcinoma in real-world clinical practice. Cancers. 2021;13(11):2786. doi:10.3390/cancers13112786
   PubMed Web of Science ®Google Scholar
• Torrens L, Montironi C, Puigvehí M, et al. Immunomodulatory effects of lenvatinib plus anti-PD1 in mice and rationale for patient enrichment in hepatocellular carcinoma. Hepatology. 2021;74:2652–2669. doi:10.1002/hep.32023
   PubMed Web of Science ®Google Scholar
• Yau T, Park JW, Finn RS, et al. Nivolumab versus sorafenib in advanced hepatocellular carcinoma (CheckMate 459): a randomised, multicentre, open-label, phase 3 trial. Lancet Oncol. 2022;23(1):77–90. doi:10.1016/S1470-2045(21)00604-5
   PubMed Web of Science ®Google Scholar
• Yau T, Kang Y-K, Kim T-Y, et al. Efficacy and safety of nivolumab plus ipilimumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib: the checkmate 040 randomized clinical trial. JAMA Oncol. 2020;6(11):e204564. doi:10.1001/jamaoncol.2020.4564
   PubMed Web of Science ®Google Scholar
• Ho WJ, Sharma G, Zhu Q, et al. Integrated immunological analysis of a successful conversion of locally advanced hepatocellular carcinoma to resectability with neoadjuvant therapy. J Immunother Cancer. 2020;8(2):e000932. doi:10.1136/jitc-2020-000932
   PubMed Web of Science ®Google Scholar
• Yarchoan M, Durham ZQ, Durham JN, et al. Feasibility and efficacy of neoadjuvant cabozantinib and nivolumab in patients with borderline resectable or locally advanced hepatocellular carcinoma (HCC). J Clin Oncol. 2021;39(suppl 3):335–335. doi:10.1200/JCO.2021.39.3_suppl.335
   Web of Science ®Google Scholar
• Zhu AX. A phase Ib study of lenvatinib (LEN) plus pembrolizumab (PEMBRO) in unresectable hepatocellular carcinoma (uHCC). ASCO, 2020(Abstract 4519). 2020.
   Google Scholar
• Abou-Alfa GK, Chan SL, Kudo M, et al.Phase 3 randomized, open-label, multicenter study of tremelimumab (T) and durvalumab (D) as first-line therapy in patients (pts) with unresectable hepatocellular carcinoma (uHCC): HIMALAYA. Am Soc Clin Oncol. 2022. doi:10.1200/JCO.2022.40.4_suppl.379
   Web of Science ®Google Scholar
• Liu J, Blake SJ, Yong MCR, et al. Improved efficacy of neoadjuvant compared to adjuvant immunotherapy to eradicate metastatic disease. Cancer Discov. 2016;6(12):1382–1399. doi:10.1158/2159-8290.CD-16-0577
   PubMed Web of Science ®Google Scholar
• Yao FY, Mehta N, Flemming J, et al. Downstaging of hepatocellular cancer before liver transplant: long-term outcome compared to tumors within Milan criteria. Hepatology. 2015;61(6):1968–1977. doi:10.1002/hep.27752
   PubMed Web of Science ®Google Scholar
• Nordness MF, Hamel S, Godfrey CM, et al. Fatal hepatic necrosis after nivolumab as a bridge to liver transplant for HCC: are checkpoint inhibitors safe for the pretransplant patient? Am J Transplant. 2020;20(3):879–883. doi:10.1111/ajt.15617
   PubMed Web of Science ®Google Scholar
• Gassmann D, Weiler S, Mertens JC, et al. Liver allograft failure after nivolumab treatment-a case report with systematic literature research. Transplant Direct. 2018;4(8):e376. doi:10.1097/TXD.0000000000000814
   PubMed Web of Science ®Google Scholar
• Pinato DJ, Cortellini A, Sukumaran A, et al. PRIME-HCC: phase Ib study of neoadjuvant ipilimumab and nivolumab prior to liver resection for hepatocellular carcinoma. BMC Cancer. 2021;21(1):301. doi:10.1186/s12885-021-08033-x
   PubMed Web of Science ®Google Scholar
• Marron TU, Fiel MI, Hamon P, et al. Neoadjuvant cemiplimab for resectable hepatocellular carcinoma: a single-arm, open-label, phase 2 trial. Lancet Gastroenterol Hepatol. 2022;7(3):219–229. doi:10.1016/S2468-1253(21)00385-X
   PubMed Web of Science ®Google Scholar
• Kaseb AO, Vence L, Blando J, et al. Immunologic correlates of pathologic complete response to preoperative immunotherapy in hepatocellular carcinoma. Cancer Immunol Res. 2019;7(9):1390–1395. doi:10.1158/2326-6066.CIR-18-0605
   PubMed Web of Science ®Google Scholar
• Rozeman EA, Menzies AM, van Akkooi ACJ, et al. Identification of the optimal combination dosing schedule of neoadjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma (OpACIN-neo): a multicentre, phase 2, randomised, controlled trial. Lancet Oncol. 2019;20(7):948–960. doi:10.1016/S1470-2045(19)30151-2
   PubMed Web of Science ®Google Scholar
• Foerster F, Galle PR. The current landscape of clinical trials for systemic treatment of HCC. Cancers. 2021;13(8):1962. doi:10.3390/cancers13081962
   PubMed Web of Science ®Google Scholar
• Tagliamonte M, Mauriello A, Cavalluzzo B, et al. Tackling hepatocellular carcinoma with individual or combinatorial immunotherapy approaches. Cancer Lett. 2020;473:25–32. doi:10.1016/j.canlet.2019.12.029
   PubMed Web of Science ®Google Scholar
• Kim JM, Cho SY, Rhu J, et al. Adjuvant therapy using ex vivo -expanded allogenic natural killer cells in hepatectomy patients with hepatitis B virus related solitary hepatocellular carcinoma: MG4101 study. Ann Hepatobiliary Pancreat Surg. 2021;25(2):206–214. doi:10.14701/ahbps.2021.25.2.206
   PubMedGoogle Scholar
• Correction. Gastroenterology. 2021;160(4):1433. doi:10.1053/j.gastro.2021.02.025
   Google Scholar
• Tseng HC, Xiong W, Badeti S, et al. Efficacy of anti-CD147 chimeric antigen receptors targeting hepatocellular carcinoma. Nat Commun. 2020;11(1):4810. doi:10.1038/s41467-020-18444-2
   PubMed Web of Science ®Google Scholar
• Sun B, Yang D, Dai H, et al. Eradication of hepatocellular carcinoma by NKG2D-based CAR-T cells. Cancer Immunol Res. 2019;7(11):1813–1823. doi:10.1158/2326-6066.CIR-19-0026
   PubMed Web of Science ®Google Scholar
• Ohira M, Hotta R, Tanaka Y, et al. Pilot study to determine the safety and feasibility of deceased donor liver natural killer cell infusion to liver transplant recipients with hepatocellular carcinoma. Cancer Immunol Immunother. 2021;71:589–599. doi:10.1007/s00262-021-03005-3
   PubMed Web of Science ®Google Scholar
• Sun C, Sun H-Y, Xiao W-H, et al. Natural killer cell dysfunction in hepatocellular carcinoma and NK cell-based immunotherapy. Acta Pharmacol Sin. 2015;36(10):1191–1199. doi:10.1038/aps.2015.41
   PubMed Web of Science ®Google Scholar
• Moehler M, Heo J, Lee HC, et al. Vaccinia-based oncolytic immunotherapy Pexastimogene Devacirepvec in patients with advanced hepatocellular carcinoma after sorafenib failure: a randomized multicenter Phase IIb trial (TRAVERSE). Oncoimmunology. 2019;8(8):1615817. doi:10.1080/2162402X.2019.1615817
   PubMed Web of Science ®Google Scholar
• Slovak R, Ludwig JM, Gettinger SN, et al. Immuno-thermal ablations - boosting the anticancer immune response. J Immunother Cancer. 2017;5(1):78. doi:10.1186/s40425-017-0284-8
   PubMed Web of Science ®Google Scholar
• Chu KF, Dupuy DE. Thermal ablation of tumours: biological mechanisms and advances in therapy. Nat Rev Cancer. 2014;14(3):199–208. doi:10.1038/nrc3672
   PubMed Web of Science ®Google Scholar
• Yoshida S, Kornek M, Ikenaga N, et al. Sublethal heat treatment promotes epithelial-mesenchymal transition and enhances the malignant potential of hepatocellular carcinoma. Hepatology. 2013;58(5):1667–1680. doi:10.1002/hep.26526
   PubMed Web of Science ®Google Scholar
• Obara K, Matsumoto N, Okamoto M, et al. Insufficient radiofrequency ablation therapy may induce further malignant transformation of hepatocellular carcinoma. Hepatol Int. 2008;2(1):116–123. doi:10.1007/s12072-007-9040-3
   PubMed Web of Science ®Google Scholar
• Marin HL, Furth EE, Olthoff K, et al. Histopathologic outcome of neoadjuvant image-guided therapy of hepatocellular carcinoma. J Gastrointestin Liver Dis. 2009;18(2):169–176.
   PubMed Web of Science ®Google Scholar
• Oyama A, Nouso K, Yoshimura K, et al. Randomized controlled study to examine the efficacy of hepatic arterial infusion chemotherapy with cisplatin before radiofrequency ablation for hepatocellular carcinoma. Hepatol Res. 2021;51(6):694–701. doi:10.1111/hepr.13633
   PubMed Web of Science ®Google Scholar
• Mehta A, Oklu R, Sheth RA. Thermal ablative therapies and immune checkpoint modulation: can locoregional approaches effect a systemic response? Gastroenterol Res Pract. 2016;2016:9251375. doi:10.1155/2016/9251375
   PubMed Web of Science ®Google Scholar
• den Brok MH, Sutmuller RPM, Nierkens S, et al. Synergy between in situ cryoablation and TLR9 stimulation results in a highly effective in vivo dendritic cell vaccine. Cancer Res. 2006;66(14):7285–7292. doi:10.1158/0008-5472.CAN-06-0206
   PubMed Web of Science ®Google Scholar
• Zhang Y, Zhang M-W, Fan -X-X, et al. Drug-eluting beads transarterial chemoembolization sequentially combined with radiofrequency ablation in the treatment of untreated and recurrent hepatocellular carcinoma. World J Gastrointest Surg. 2020;12(8):355–368. doi:10.4240/wjgs.v12.i8.355
   PubMed Web of Science ®Google Scholar
• Lemaire M, Lucidi V, Bouazza F, et al. Selective internal radiation therapy (SIRT) before partial hepatectomy or radiofrequency destruction for treatment of hepatocellular carcinoma in cirrhotic patients: a feasibility and safety pilot study. HPB (Oxford). 2018;20(7):641–648. doi:10.1016/j.hpb.2018.01.006
   PubMed Web of Science ®Google Scholar
• van den Bijgaart RJ, Eikelenboom DC, Hoogenboom M, et al. Thermal and mechanical high-intensity focused ultrasound: perspectives on tumor ablation, immune effects and combination strategies. Cancer Immunol Immunother. 2017;66(2):247–258. doi:10.1007/s00262-016-1891-9
   PubMed Web of Science ®Google Scholar
• Duffy AG, Ulahannan SV, Makorova-Rusher O, et al. Tremelimumab in combination with ablation in patients with advanced hepatocellular carcinoma. J Hepatol. 2017;66(3):545–551. doi:10.1016/j.jhep.2016.10.029
   PubMed Web of Science ®Google Scholar
• Liu D, Liu M, Su L, et al. Transarterial chemoembolization followed by radiofrequency ablation for hepatocellular carcinoma: impact of the time interval between the two treatments on outcome. J Vasc Interv Radiol. 2019;30(12):1879–1886. doi:10.1016/j.jvir.2019.07.029
   PubMed Web of Science ®Google Scholar
• Choe WH, Kim YJ, Park HS, Park SW, Kim JH, Kwon SY. Short-term interval combined chemoembolization and radiofrequency ablation for hepatocellular carcinoma. World J Gastroenterol. 2014;20(35):12588–12594. doi:10.3748/wjg.v20.i35.12588
   PubMed Web of Science ®Google Scholar
• Fujiki M, Aucejo F, Kim R. General overview of neo-adjuvant therapy for hepatocellular carcinoma before liver transplantation: necessity or option? Liver Int. 2011;31(8):1081–1089. doi:10.1111/j.1478-3231.2011.02473.x
   PubMed Web of Science ®Google Scholar
• Andreana L, Burroughs AK. Treatment of early hepatocellular carcinoma: how to predict and prevent recurrence. Dig Liver Dis. 2010;42(Suppl 3):S249–57. doi:10.1016/S1590-8658(10)60513-0
   PubMedGoogle Scholar
• Zhu AX, Kang Y-K, Yen C-J, et al. Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased alpha-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2019;20(2):282–296. doi:10.1016/S1470-2045(18)30937-9
   PubMed Web of Science ®Google Scholar
• Zhu AX, Park JO, Ryoo B-Y, et al. Ramucirumab versus placebo as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib (REACH): a randomised, double-blind, multicentre, phase 3 trial. Lancet Oncol. 2015;16(7):859–870. doi:10.1016/S1470-2045(15)00050-9
   PubMed Web of Science ®Google Scholar
• Zhu AX, Baron AD, Malfertheiner P, et al. Ramucirumab as second-line treatment in patients with advanced hepatocellular carcinoma: analysis of REACH trial results by child-pugh score. JAMA Oncol. 2017;3(2):235–243. doi:10.1001/jamaoncol.2016.4115
   PubMed Web of Science ®Google Scholar
• Huang AC, Postow MA, Orlowski RJ, et al. T-cell invigoration to tumour burden ratio associated with anti-PD-1 response. Nature. 2017;545(7652):60–65. doi:10.1038/nature22079
   PubMed Web of Science ®Google Scholar
• Finn RS, Kudo M, Cheng A-L, et al. Pharmacodynamic biomarkers predictive of survival benefit with lenvatinib in unresectable hepatocellular carcinoma: from the phase III REFLECT study. Clin Cancer Res. 2021;27:4848–4858. doi:10.1158/1078-0432.CCR-20-4219
   PubMed Web of Science ®Google Scholar
• Xue F, Shi S, Zhang Z, et al. Application of a novel liquid biopsy in patients with hepatocellular carcinoma undergoing liver transplantation. Oncol Lett. 2018;15(4):5481–5488. doi:10.3892/ol.2018.8019
   PubMed Web of Science ®Google Scholar
• Sun YF, Xu Y, Yang X-R, et al. Circulating stem cell-like epithelial cell adhesion molecule-positive tumor cells indicate poor prognosis of hepatocellular carcinoma after curative resection. Hepatology. 2013;57(4):1458–1468. doi:10.1002/hep.26151
   PubMed Web of Science ®Google Scholar
• Bagaev A, Kotlov N, Nomie K, et al. Conserved pan-cancer microenvironment subtypes predict response to immunotherapy. Cancer Cell. 2021;39(6):845–865 e7. doi:10.1016/j.ccell.2021.04.014
   PubMed Web of Science ®Google Scholar
• Xu RH, Wei W, Krawczyk M, et al. Circulating tumour DNA methylation markers for diagnosis and prognosis of hepatocellular carcinoma. Nat Mater. 2017;16(11):1155–1161. doi:10.1038/nmat4997
   PubMed Web of Science ®Google Scholar
• He G, Chen Y, Zhu C, et al. Application of plasma circulating cell-free DNA detection to the molecular diagnosis of hepatocellular carcinoma. Am J Transl Res. 2019;11(3):1428–1445.
   PubMed Web of Science ®Google Scholar
• Memarnejadian A, Meilleur CE, Shaler CR, et al. PD-1 blockade promotes epitope spreading in anticancer CD8 + T cell responses by preventing fratricidal death of subdominant clones to relieve immunodomination. J Immunol. 2017;199(9):3348–3359. doi:10.4049/jimmunol.1700643
   PubMed Web of Science ®Google Scholar
• Liu J, Rozeman EA, O’Donnell JS, et al. Batf3 + DCs and type I IFN are critical for the efficacy of neoadjuvant cancer immunotherapy. Oncoimmunology. 2019;8(2):e1546068. doi:10.1080/2162402X.2018.1546068
   PubMed Web of Science ®Google Scholar
• Salmon H, Idoyaga J, Rahman A, et al. Expansion and activation of CD103(+) dendritic cell progenitors at the tumor site enhances tumor responses to therapeutic PD-L1 and BRAF inhibition. Immunity. 2016;44(4):924–938. doi:10.1016/j.immuni.2016.03.012
   PubMed Web of Science ®Google Scholar
• Yi C, Chen L, Lin Z, et al. Lenvatinib targets FGFR4 to enhance antitumor immune response of anti-PD-1 in hepatocellular carcinoma. Hepatology. 2021;74:2544–2560. doi:10.1002/hep.31921
   PubMed Web of Science ®Google Scholar
• Liu L, Bai X, Wang J, et al. Combination of TMB and CNA stratifies prognostic and predictive responses to immunotherapy across metastatic cancer. Clin Cancer Res. 2019;25(24):7413–7423. doi:10.1158/1078-0432.CCR-19-0558
   PubMed Web of Science ®Google Scholar
• Samstein RM, Lee C-H, Shoushtari AN, et al. Tumor mutational load predicts survival after immunotherapy across multiple cancer types. Nat Genet. 2019;51(2):202–206. doi:10.1038/s41588-018-0312-8
   PubMed Web of Science ®Google Scholar
• Cristescu R, Mogg R, Ayers M, et al. Pan-tumor genomic biomarkers for PD-1 checkpoint blockade-based immunotherapy. Science. 2018;362(6411). doi:10.1126/science.aar3593
   PubMed Web of Science ®Google Scholar